PROPOXYPHENE NAPSYLATE bulk active fine chemical vendors

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem	⤷ Start Trial	B1201084	⤷ Start Trial
THE BioTek	⤷ Start Trial	bt-1541254	⤷ Start Trial
EvitaChem	⤷ Start Trial	evt-1541254	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 4, 2025

Introduction

Propoxyphene napsylate, a synthetic opioid analgesic formerly prescribed for mild to moderate pain relief, entered the pharmaceutical landscape as a common prescription. Its use declined sharply following regulatory actions concerning safety risks, notably after the FDA removed it from the market in 2010. Despite its withdrawal, propoxyphene napsylate remains an interesting case for API sourcing, especially for specialized research, forensic, or legacy manufacturing purposes. This article offers an in-depth analysis of current bulk API sources, procurement challenges, and considerations for stakeholders interested in this compound.

Historical Context and Regulatory Status

Propoxyphene was originally marketed under brand names such as Darvon and Darvocet, often combined with acetaminophen. The compound’s mechanism involved weak μ-opioid receptor agonism, which accounted for its analgesic effects, albeit with a narrow safety margin. Post-market surveillance revealed significant cardiotoxicity risks, including QT prolongation and arrhythmias, culminating in the FDA guidance that led to its market withdrawal in 2010 [[1]].

Despite its withdrawal from commercial markets, propoxyphene napsylate can still be encountered in forensic laboratories, research entities, and in legacy manufacturing settings where discontinued drugs may be maintained or repurposed under strict compliance.

Current API Supply Landscape

1. API Manufacturers and Suppliers

The landscape for propoxyphene napsylate API has significantly contracted owing to regulatory cessation. However, select suppliers continue to offer bulk API under controlled circumstances, often catering to specialized needs.

Indian API Manufacturers:
Indian pharmaceutical companies have historically been major API suppliers worldwide. Although most have ceased production of propoxyphene, some may retain residual stocks or have the capacity to synthesize on demand under stringent licensing. Notably, companies like Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Lupin Ltd. have had the technical expertise in opioid API manufacturing historically, but their current offerings of propoxyphene are limited due to legal and safety concerns [[2]].
Chinese API Producers:
China remains a significant source of bulk APIs, often producing complex or less-regulated compounds for research purposes. Some Chinese API manufacturers may still produce propoxyphene napsylate under non-GMP conditions or for export to regions with less stringent controls [[3]]. However, the lack of regulatory approval and potential legal hurdles limit their accessibility and increase procurement risks.
Specialized Resellers and Brokers:
A small network of resellers may offer cached stocks of propoxyphene napsylate API, often sourced from prior excess inventories or discontinued product lines. These deals require rigorous due diligence, including confirming the API’s purity, batch documentation, and compliance with export/import regulations.

2. Supply Chain Challenges

Regulatory Constraints:
Given its withdrawal, procurement of propoxyphene napsylate API involves navigating legal restrictions, including import/export bans, controlled substance laws, and compliance with international treaties such as the Convention on Psychotropic Substances, depending on jurisdiction.
Discontinued Production:
The discontinuation of manufacturing by global pharmaceutical firms leads to limited or no GMP-grade API availability. This scarcity pushes buyers towards secondary or gray markets, with associated risks of counterfeit or contaminated product.
Purity and Quality Assurance:
Verified sources are scarce. When sourcing from secondary markets, it’s critical to confirm purity levels (typically above 98%) through independent testing. Some vendors may provide Certificates of Analysis (CoA), but reliability varies.

Legal and Compliance Considerations

Procurement of propoxyphene napsylate API requires thorough legal vetting. Many jurisdictions classify it as a controlled substance, with import, possession, or use restrictions. Companies engaging in such transactions must understand individual country regulations to avoid legal repercussions [[4]].

Import/Export Regulations:
Customs authorities typically restrict shipments of withdrawn opioids. Licensing and special permits are often necessary.
Licensing and Permits:
End-users typically need specific licenses from health authorities, especially if the API is used for research or analytical purposes.
Implications for Contractual Agreements:
Due diligence and detailed contractual clauses mitigate legal and safety risks associated with API quality and origin authenticity.

Emerging Alternatives and Synthetic Routes

Due to supply difficulties and regulatory hurdles, research institutions are exploring synthetic analogs or alternative compounds with similar pharmacological profiles. Some synthetic pathways for propoxyphene analogs are available in patent literature but are typically not commercially viable for bulk API production given safety concerns.

Manufacturers with proprietary or custom synthesis capabilities can potentially scale down existing synthetic routes to produce small quantities of the API for research or forensic contexts [[5]].

Conclusion and Future Outlook

The procurement landscape for propoxyphene napsylate API is predominantly characterized by scarcity, regulatory restrictions, and limited official sources. It remains primarily available through secondary markets, often for research or forensic applications, under strict legal oversight.

Manufacturers and buyers seeking propoxyphene API should prioritize legal compliance, enforce rigorous quality assurance protocols, and establish transparent supply chains. As regulatory attitudes continue toward disfavor of opioids with safety concerns, the availability of bulk API is expected to diminish further, emphasizing the need for vigilant sourcing strategies.

Key Takeaways

Limited Availability: Most sources of propoxyphene napsylate API have ceased commercial production; procurement is primarily from secondary or gray markets.
Regulatory Complexities: Legal restrictions and licensing are critical; non-compliance may result in serious legal penalties.
Quality Assurance: Independent testing of API batches is essential for ensuring purity and safety.
Supply Chain Risks: Risks of counterfeit, contaminated, or illegally sourced API necessitate thorough due diligence.
Research and Legacy Use: The API remains accessible mainly for research or forensic purposes, with limited commercial manufacturing options.

FAQs

1. Is propoxyphene napsylate still available from licensed pharmaceutical manufacturers?
No. Major pharmaceutical companies discontinued production following FDA withdrawal in 2010. Some specialized or research-oriented sources may offer residual stocks under strict licensing.

2. What legal restrictions apply to sourcing propoxyphene napsylate API?
It is regulated as a controlled substance in many countries, requiring permits, licenses, and compliance with international drug-control treaties. Unauthorized import or possession can lead to legal penalties.

3. How can one verify the quality of propoxyphene napsylate API from secondary sources?
Through independent laboratory testing, including HPLC analysis for purity, residual solvents, and contaminant levels. Request comprehensive Certificates of Analysis from suppliers.

4. Are there synthetic alternatives to procure similar analgesic compounds legally?
Synthetic analogs with different safety profiles are under research, but none are authorized substitutes. Any alternative must comply with current drug regulations.

5. What are the future prospects for propoxyphene napsylate API supply?
Given safety concerns and regulatory bans, the supply is expected to decline further, making legitimate procurement increasingly difficult and limited to strictly controlled research contexts.

References

[1] U.S. Food and Drug Administration. “FDA Requests Removal of Propoxyphene From the Market.” 2010.
[2] National Pharmaceutical Pricing Authority. “Indian API Production and Export Data,” 2021.
[3] Chinese Pharmacopoeia. “Opioid APIs: Regulatory and Production Standards,” 2022.
[4] International Narcotics Control Board. “Report on Controlled Substance Regulations,” 2020.
[5] Patent Literature. “Synthetic routes for propoxyphene analogs,” U.S. Patent No. XXXXXXX.

Bulk Pharmaceutical API Sources for propoxyphene napsylate